Laurus Labs Q1 Profit Soars 1144%

  Published 8 months ago

Laurus Labs posted strong Q1 FY26 growth, driven by CDMO surge, margin gains, and strategic expansion in Andhra Pradesh.

  • CDMO revenue doubled YoY to Rs 522 crore, while FDF rose 50%, supporting robust business performance.
  • EBITDA jumped 127% to Rs 389 crore; margins expanded due to operating leverage and better CDMO product mix.
  • Andhra Pradesh allotted 531.77 acres for Rs 5,630 crore Laurus Pharma Zone, expected to create 6,350 jobs.

You might like these

Indian Sucrose Ltd Stock Surges 20%

Premier Energies' Strong Q2 Surge

US Tariff Spike Hits Indian Markets

Zerodha FY25 Earnings Slip Due to Rules

MobiKwik Stock Rises on Broker License, Down 44% Since IPO

Tariff Shock: US Output Down, Prices Up

China's Economic Boost: Policies & Foreign Investment

News that matters the most ⚡